management
advanced
endometrial
adenocarcinoma
medroxyprogesterone
acetate
a
basis
progestin
therapy
patients
advanced
endometrial
adenocarcinoma
presented
criteria
selection
patients
hormone
therapy
sched
ule
administration
medroxyprogester
one
provera
discussed
evaluation
patients
objective
changes
i.e
visual
palpable
histologic
roentgeno
logic
means
revealed
complete
partial
remission
significant
palliation
patients
per
cent
response
droxyprogesterone
therapy
apparently
re
lated
degree
differentiation
pri
mary
neoplasm
welldifferentiated
le
sions
responsive
documentation
tumor
effect
serial
biopsies
treatment
provides
index
histologic
changes
progestin
produces
suscep
tible
cases
effects
therapy
upon
serial
urinary
hormone
excretion
rates
documented
several
patients
basis
experience
treat
ment
patients
advanced
endometrial
adenocarcinoma
potent
progestin
medroxyprogesterone
seems
justified
